Erdafitinib and Nevirapine Suspension
Determining the interaction of Erdafitinib and Nevirapine Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes. MANAGEMENT: According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Professional:ADJUST DOSE: Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.
MANAGEMENT: According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.
- "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Generic Name: nevirapine
Brand name: Viramune, Viramune XR
Synonyms: Nevirapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erdafitinib-Nevirapine Tablets
- Erdafitinib-New Day
- Erdafitinib-New Terocin
- Erdafitinib-Nexa Plus
- Erdafitinib-Nexa Select
- Erdafitinib-Nexafed
- Nevirapine Suspension-Erelzi Prefilled Syringe
- Nevirapine Suspension-Erelzi Sensoready Pen
- Nevirapine Suspension-Erelzi Subcutaneous
- Nevirapine Suspension-Ergocalciferol
- Nevirapine Suspension-Ergocalciferol Capsules and Tablets
- Nevirapine Suspension-Ergocalciferol Solution